WHO loses communication with contacts in Al-Shifa hospital in Gaza amid reports of attacks
WHO has lost communication with its contacts in Al-Shifa Hospital in northern Gaza. As horrifying reports of the hospital facing repeated attacks continue to emerge, we assume our contacts joined tens of thousands of displaced people who had sought shelter on the hospital grounds and are fleeing the area. There are reports that some people […]
Tuberculosis response recovering from pandemic but accelerated efforts needed to meet new targets - embargoed until 16.00 on 07 November
The World Health Organization (WHO) 2023 Global tuberculosis (TB) report underscores a significant worldwide recovery in the scale-up of TB diagnosis and treatment services in 2022. It shows an encouraging trend starting to reverse the detrimental effects of COVID- 19 disruptions on TB services. Featuring data from 192 countries and areas, the report shows that […]
WHO welcomes decision by Egypt to receive patients from Gaza Strip
The World Health Organization (WHO) welcomes Egypt’s decision to accept 81 injured and sick people from the Gaza Strip for treatment. WHO has been working to support the Egyptian Ministry of Health and Population in planning and establishing a comprehensive triage, stabilization, and medical evacuation system, by providing ongoing training for health care staff. WHO […]
Significant Achievement under Special Campaign 3.0 in Department of Health and Family Welfare
The Department of Health and Family Welfare (DoHFW) conducted Special Campaign 3.0 on Swachhata and disposal of pending matters within the Department (HQ) and all its Attached & Subordinate Offices, Autonomous Bodies and CPSE located in various parts of the country. The objectives of the campaign were to minimize pendency, institutionalize swachhata, strengthen internal monitoring […]
Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints
Elevidys-treated boys aged 4-7 years with Duchenne showed an increase on the North Star Ambulatory Assessment (NSAA), a measure of motor function, compared to placebo at 52 weeks but the primary endpoint was not met For all key pre-specified secondary functional endpoints, time to rise and 10-metre walk test across age groups, clinically meaningful and […]
WHO outlines crucial research priorities for better refugee and migrant health
The World Health Organization (WHO) has published its first-ever Global research agenda on health, migration and displacement to guide research efforts to understand and address the health needs of migrants, refugees, and all forcibly displaced populations and shape responsive policies and practices worldwide. There are one billion people currently leaving their homes by choice or […]
FDA approves Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)
RVO is the third indication for Vabysmo, in addition to neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema Approval is based on two phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept Vabysmo also demonstrated rapid and robust drying of retinal fluid Additional U.S. label update across indications […]
Positive topline phase III results show Roche's Vabysmo improved vision for people living with retinal vein occlusion (RVO)
Vabysmo achieved its primary endpoint of non-inferiority to aflibercept in RVO in the BALATON and COMINO clinical trials Vabysmo was generally well tolerated, with a safety profile consistent with previous trials Vabysmo is the first and only treatment that targets and inhibits two disease pathways involving Ang-2 and VEGF-A, linked to a number of vision-threatening […]
Early treatment with Roche's OCREVUS leads to reduced disease progression and healthcare costs; nine-year safety data reinforce favourable benefit-risk profile
77% of early-stage relapsing-remitting multiple sclerosis (RRMS) patients who had not received prior treatment achieved no evidence of disease activity (NEDA) at two years Initiation of OCREVUS as first-line treatment reduces relapses, hospitalisations and costs compared with using OCREVUS in second-line setting Nine-year long-term safety data for OCREVUS further reinforce favourable benefit-risk profile; more than […]
WHO calls for immediate release, access to, and medical support for hostages taken by Hamas
Gravely concerned by the humanitarian and health situation facing approximately 200 people, including health workers and up to 30 children, abducted from Israel by Hamas and other armed groups on 7 October 2023, the World Health Organization (WHO) today reiterated its call for the immediate release of all the hostages, along with urgent access to […]
